Picture of PharmaSGP Holding SE logo

PSG PharmaSGP Holding SE News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapHigh Flyer

Brief: PharmaSGP Q1 EBITDA Up 135% To EUR 5.0 Mln

May 17 (Reuters) - PHARMASGP HOLDING SE  PSGG.DE :
    * ANOTHER REVENUE RECORD – Q1 2022 REVENUES UP 67%
YEAR-ON-YEAR
    * Q1 EBITDA ROSE 135 PERCENT TO 5.0 MILLION EUR
    * ADJUSTED EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND
AMORTIZATION (ADJUSTED EBITDA) AMOUNTED TO EUR 5.0 MILLION FOR
FIRST THREE MONTHS OF 2022, REPRESENTING A YEAR-ON-YEAR GROWTH
OF 135%
    * Q1 REVENUE EUR 20.6 MILLION
    * FOR 2022 FINANCIAL YEAR, REVENUES ARE EXPECTED TO GROW BY
AT
LEAST 19.5% TO BETWEEN EUR 78 MILLION AND EUR 82 MILLION
    * ADJUSTED EBITDA MARGIN IS EXPECTED TO INCREASE
YEAR-ON-YEAR TO
REACH A LEVEL BETWEEN 30% AND 33%
    * OUTLOOK 2022: ADJUSTED EBITDA IN A RANGE BETWEEN EUR 23.4
AND
27.1 MILLION

Source text for Eikon:  ID:nEQ9Dt9z4a 
Further company coverage:  PSGG.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on PharmaSGP Holding SE

See all news